{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T05:30:05Z","timestamp":1734672605982,"version":"3.32.0"},"reference-count":0,"publisher":"MJH Life Sciences","issue":"3812","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,25]]},"abstract":"<jats:p>Introduction: There are limited data available regarding patient outcomes in those who would have been ineligible to receive therapy based on the original clinical trial eligibility criteria. We decided to conduct a retrospective study to evaluate outcomes based on clinical trial eligibility in patients with metastatic non\u2013small cell lung cancer (NSCLC).\n\nMethods: A retrospective chart review of all patients with metastatic NSCLC who received first-line systemic therapy at a single academic institution was performed. Each patient\u2019s chart was reviewed to determine if they would have qualified for the phase 3 clinical trial that led to the approval of the specific treatment regimen which they received. Data were analyzed to determine if there was a difference in survival time between those who would have been eligible compared with those who were ineligible for the clinical trial of the treatment regimen administered.\n\nResults: There were 170 patients with a diagnosis of metastatic NSCLC who received first-line systemic therapy. Of these, 109 received combined chemotherapy, 25 received immunotherapy, and 36 received targeted therapy. There is a statistically significant difference in the restricted mean survival time between the eligible and ineligible groups in those who received combined chemotherapy (19.9 months vs 13.2 months; P\u2006=\u2006.03), but not in either the immunotherapy group (22.4 months vs 12.9 months; P = .06) or the targeted therapy group (57.7 months vs 39.0 months; P\u2006=\u2006.14).\n\nConclusion: These data support less restrictive clinical trial eligibility criteria for those with metastatic NSCLC. This is especially true regarding both targeted therapy and immunotherapy treatment regimens.<\/jats:p>","DOI":"10.46883\/2024.25921032","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T16:17:59Z","timestamp":1734625079000},"page":"462-468","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Trial Eligibility and Outcomes in Patients With Metastatic NSCLC Treated Outside of Clinical Trials"],"prefix":"10.46883","member":"25947","published-online":{"date-parts":[[2024,12,5]]},"container-title":["ONCOLOGY"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T16:18:01Z","timestamp":1734625081000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cancernetwork.com\/view\/clinical-trial-eligibility-and-outcomes-in-patients-with-metastatic-nsclc-treated-outside-of-clinical-trials"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,25]]},"references-count":0,"issue-title":["December 2024"],"journal-issue":{"issue":"3812","published-online":{"date-parts":[[2024,12,4]]},"published-print":{"date-parts":[[2024,11,25]]}},"URL":"https:\/\/doi.org\/10.46883\/2024.25921032","relation":{},"ISSN":["0890-9091"],"issn-type":[{"value":"0890-9091","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,25]]}}}